Catalin Sorin Buhimschi

7935496, May 3, 2011

May 17, 2010

12/781474

Catalin S. Buhimschi - New Haven CT, US
Irina Buhimschi - New Haven CT, US
Errol Norwitz - Newton MA, US

Yale University - New Haven CT

G01N 33/53
G01N 33/543

435 721, 435 71, 436501, 436518, 530300, 530350

The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.

8263342, Sep 11, 2012

Oct 27, 2006

12/084004

Catalin S. Buhimschi - New Haven CT, US
Irina Buhimschi - New Haven CT, US

Yale University - New Haven CT

G01N 33/53

435 71, 436518

The invention relates, in part, to methods of using proteomic biomarkers to diagnose preeclampsia. In some aspects the invention, in part, relates to the detection of serpina-1 polypeptide and/or albumin polypeptide in samples from pregnant subjects. Samples from subjects may be compared to control samples to diagnose preeclampsia and/or to determine the onset, progression, or regression of preeclampsia in a subject. The invention also relates, in part, to screening methods to identify agents that can be used to treat preeclampsia and to determine the efficacy of a preeclampsia treatment. The invention, in part, also includes kits that are useful to diagnose and assess preeclampsia in a subject.

20050233400, Oct 20, 2005

Mar 3, 2005

11/071790

Carl Weiner - Towson MD, US
Irina Buhimschi - New Haven CT, US
Catalin Buhimschi - New Haven CT, US

G01N033/53
G01N033/537

435007920

Through determination of the presence or absence of proteomic biomarkers within an amniotic environment, the present invention provides for the identification of the condition(s) within the amniotic environment and allows for predictive indication of the success of a pregnancy under the condition(s) and courses of treatment for the condition(s). The present invention further allows for a predictive indication of the success of a cerclage procedure performed on a cervix which supports the amniotic environment under the condition(s).

20060183175, Aug 17, 2006

Dec 21, 2005

11/314073

Catalin Buhimschi - New Haven CT, US
Irina Buhimschi - New Haven CT, US
Errol Norwitz - Madison CT, US

Yale University - New Haven CT

G01N 33/537
G01N 33/53
G01N 33/543

435007920

The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.

20110280863, Nov 17, 2011

Nov 2, 2009

13/126757

Catalin S. Buhimschi - New Haven CT, US
Irina Buhimschi - New Haven CT, US
Charles G. Glabe - Irvine CA, US

Regents of the University of California, The - Oakland CA
Yale University - New Haven CT

A61K 39/395
G01N 33/68
C07C 291/04
A61K 31/13
C07K 14/00
G01N 33/566
C40B 30/04

4241301, 436501, 436 86, 506 9, 514644, 530350, 564297

Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

20120021442, Jan 26, 2012

Jul 28, 2011

13/193421

Catalin S. Buhimschi - New Haven CT, US
Irina Buhimschi - New Haven CT, US
Vineet Bhandari - Cheshire CT, US

Yale University - New Haven CT

G01N 33/566

435 792, 436501

Described herein are biomarkers, such as protein biomarkers, which are diagnostic of and predictive for complications that result from an in utero encounter, such as an infection by the fetus, that can lead to premature birth (PTB). The biomarkers can be used to identify fetuses and newborns at risk for complications of PTB, such as (Early Onset Neonatal Sepsis) EONS, intra-ventricular hemorrhage (IVH) and other poor outcomes.

20120040371, Feb 16, 2012

Mar 21, 2011

13/053045

Catalin S. Buhimschi - New Haven CT, US
Irina Buhimschi - New Haven CT, US
Errol Norwitz - Newton MA, US

Yale University - New Haven CT

G01N 33/573

435 74

The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.

20190353662, Nov 21, 2019

May 8, 2019

16/406942

- New Haven CT, US
Catalin S. Buhimschi - Columbus OH, US
Michael Choma - Hamden CT, US
Hemant Tagare - North Haven CT, US
Stephan Michael Jonas - Alsdorf, DE

Yale University - New Haven CT

G01N 33/68
G01N 33/52

Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia.